Antibiotics

Rieckmann, Karl H.

doi:10.1007/978-3-642-69254-3_14

Cited by 4 publications

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies with antibiotics in experimental malaria models have revealed antimalar ial potentials in three groups, namely ( 1) tetracyclines, (2) lincosamides and (3) macrolides [Puri and Dutta, 1982;Rieckmann, 1984]. However, the use of tetra cyclines is contraindicated in pregnant women and infants because of the deposi tion of tetracycline complexes in develop ing bone and teeth [WHO, 1981], and the use of the lincosamide antibiotic, clindam ycin, in combination has been observed to increase the incidence and severity of gas trointestinal side effects [WHO, 1984].…”

Section: Introductionmentioning

confidence: 99%

Spectrum of the Antimalarial Activity of a New Macrolide Antibiotic Midecamycin in Mice and Monkeys

Puri

Dutta²

1989

Chemotherapy

View full text Add to dashboard Cite

The antimalarial activity of a new macrolide antibiotic, midecamycin, has been evaluated against a sensitive strain of Plasmodium berghei, a chloroquine-resistant strain of P. yoelii nigeriensis and a simian parasite, P. cynomolgi B. The ED₅₀ and ED₉₀values of this antibiotic administered in two divided daily doses were found to be 37.15 ± 3.51 and 100.84 ± 7.54 mg/kg, respectively, against P. berghei and 362.34 ± 85.33 and 878.04 ± 10.02 mg/kg, respectively, against P. yoelii nigeriensis. Doses above 45 mg/kg for 4 days significantly extended the mean survival time of treated mice infected with either of the two parasites. However, no appreciable blood schizontocidal (at 100 mg/kg x 7 days), anti-relapse (at 100 mg/kg x 7 days) or causal prophylactic activities (at 200 mg/kg x 3 days) were observed against P. cynomolgi infection in rhesus monkeys.

show abstract

Section: Introductionmentioning

confidence: 99%